RNS Number : 3079D MaxCyte, Inc. 06 September 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , September 6, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 1550D MaxCyte, Inc. 06 September 2024 MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference Rockville, MD , September 6, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
ROCKVILLE, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative
RNS Number : 7585C MaxCyte, Inc. 03 September 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, MD , September 3, 2024 : MaxCyte Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance
RNS Number : 1597C MaxCyte, Inc. 29 August 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , August 29, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 4316Z MaxCyte, Inc. 07 August 2024 MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2024 ROCKVILLE, MD , August 7, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies
RNS Number : 4498Z MaxCyte, Inc. 07 August 2024 MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD , August 7, 2024 — MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing
ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative
RNS Number : 8744Y MaxCyte, Inc. 01 August 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, MD , August 1, 2024 : MaxCyte Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 4698Y MaxCyte, Inc. 31 July 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , July 31, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to
